Medigen Vaccine Biologics

What Medigen Vaccine Biologics does

Medigen Vaccine Biologics Corp. (高端疫苗生物製劑股份有限公司) is a Taiwan-based biopharmaceutical company founded in 2012 and listed on the Taiwan OTC (TPEx: 6547.TWO) since August 2015. The company develops and manufactures preventive vaccines using proprietary cell-based culture technology at its PIC/S GMP-certified, BSL-2 compliant facility in the Hsinchu Biomedical Science Park. Its commercial portfolio comprises three products: ENVACGEN® (inactivated, adjuvanted enterovirus A71 vaccine with 100% actual / 96.8% statistical efficacy in Phase III trials and 5-year immune persistence, approved in Taiwan April 2023 and Vietnam March 2026), MVC-COV1901 (recombinant SARS-CoV-2 spike protein vaccine adjuvanted with Dynavax's CpG 1018, Taiwan EUA July 2021), and a Quadrivalent Influenza Vaccine included in Taiwan's National Immunization Program since 2023. The pipeline includes Enterovirus D68, multivalent enterovirus, and dengue vaccine candidates.

The business operates a hybrid B2G/B2B model generating revenue through (1) direct government procurement via national immunization programs in Taiwan and Vietnam (MVC holds >97% market share for enterovirus vaccines in Taiwan), (2) exclusive regional distribution partnerships — notably Substipharm Biologics covering Vietnam and broader ASEAN markets, and (3) technology licensing, exemplified by becoming the first private manufacturer to out-license COVID-19 vaccine technology through WHO C-TAP and the Medicines Patent Pool in August 2023. Key technology partnerships include US NIH (dengue and COVID-19), Dynavax (CpG 1018 adjuvant), GC Pharma (QIV commercialization), and Vietnam's NIHE (clinical trials). Pricing is not publicly disclosed and operates through institutional/tender-based procurement. Strategic priorities evident in 2025-2026 data include ASEAN geographic expansion, capacity buildout via a new BSL-2 manufacturing facility groundbreaking in January 2026, and pipeline diversification into next-generation enterovirus vaccines.

Name

Medigen Vaccine Biologics

Legal name

高端疫苗生物製劑股份有限公司

Website

https://medigenvac.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Medigen Vaccine Biologics is a Taiwan-based biopharmaceutical company developing cell-based preventive vaccines — ENVACGEN® (EV-A71), MVC-COV1901 (COVID-19), and quadrivalent influenza — sold to government health authorities through national immunization programs and regional distribution partnerships across Asia-Pacific.

Ownership category

akta.pro rank

Product category

Vaccines and Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Adult Vaccines (HLAIAEAB)

Keywords

• Vaccine development
• Cell-based vaccines
• Enterovirus vaccines
• Biopharmaceutical manufacturing
• Immunization biologics

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Commercial sales of approved vaccines including ENVACGEN® (EV-A71 vaccine) and quadrivalent influenza vaccine. Products are sold through national immunization programs and private market channels. MVC maintains over 97% market share in Taiwan for enterovirus vaccines.
2. Technology Licensing: Out-licensing of vaccine technology and know-how through WHO C-TAP initiative. MVC licenses its COVID-19 vaccine MVC-COV1901 technology to manufacturers globally, including transfer of IP, proprietary know-how, and staff training.
3. Distribution Partnership Revenue: Revenue from regional distribution partnerships such as the Substipharm Biologics agreement for ENVACGEN® in Vietnam and ASEAN markets, where partners handle local marketing and distribution.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Medigen Vaccine Biologics is a biopharmaceutical company that develops, manufactures, and commercializes preventive vaccines using proprietary cell-based technology. Its commercial products include ENVACGEN (enterovirus 71 vaccine for infants from 2 months of age), MVC-COV1901 (COVID-19 vaccine), and a quadrivalent influenza vaccine included in Taiwan's National Immunization Program. The company also pursues vaccine technology out-licensing through the WHO C-TAP initiative and operates PIC/S GMP-certified BSL-2 manufacturing facilities.

Product overview

Medigen Vaccine Biologics is a biopharmaceutical company focused on developing and manufacturing preventive vaccines using cell-based technologies. The company operates a PIC/S GMP-certified manufacturing facility and has three commercial products: ENVACGEN® (enterovirus A71 vaccine with 96.8-100% efficacy, first approved for infants from 2 months), MVC-COV1901 (COVID-19 vaccine, Taiwan's first domestic vaccine with EUA in 2021), and quadrivalent influenza vaccine (QIV, included in Taiwan National Immunization Program since 2023). The product portfolio is complemented by a development pipeline including Enterovirus D68 vaccine, multivalent enterovirus vaccine, and dengue vaccine. The company out-licensed its COVID-19 vaccine technology to WHO C-TAP, making it the first private manufacturer to share vaccine technology through this global health mechanism.

Differentiator

Problem solved

Functional benefit

Brands

• ENVACGEN®: Enterovirus 71 (EV-A71) vaccine product brand, marketed in Taiwan and Vietnam for protection against hand, foot, and mouth disease.
• 福喜健 (Fuxijian)

Products and services

• ENVACGEN® (恩穩健) Enterovirus A71 Vaccine An inactivated, adjuvanted enterovirus 71 (EV-A71) vaccine for infants and young children, providing 96.8-100% protection against EV-A71 infections which cause hand, foot, and mouth disease (HFMD) with severe neurological complications. It is the only EV71 vaccine approved for administration starting from two-month-old infants, with demonstrated immune persistence lasting at least five years and cross-protection against subgenotypes B5 and C4.
• MVC-COV1901 COVID-19 Vaccine A recombinant SARS-CoV-2 spike protein (S-2P) vaccine adjuvanted with Dynavax's CpG 1018 adjuvant. Developed and manufactured as Taiwan's first domestic SARS-CoV-2 vaccine, receiving emergency use authorization in July 2021. Administered in over 3 million doses across 7 countries and selected for the WHO COVID-19 Solidarity Trial Vaccines.
• Quadrivalent Influenza Vaccine (QIV) A four-strain seasonal influenza vaccine that entered Taiwan's National Immunization Program in 2023. The company also produces a trivalent version marketed as 'Fuxijian' (福喜健) for employee and public use, using cell-based production technology.
• COVID-19 Vaccine Technology Transfer (WHO C-TAP)

Quantifiable outcome

• 100% protection against EV-A71 infections in vaccinated group during Phase III trial (0 cases vaccine vs 22 placebo, P<0.0001)
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Substipharm BiologicscoreChannel Partner/ Reseller/ Distributor · 9 January 2025Exclusive distribution agreement for ENVACGEN® Enterovirus A71 vaccine in Vietnam with expansion planned to Thailand, Philippines, Indonesia, Malaysia, and Singapore. Substipharm Biologics handles local marketing and distribution leveraging their expertise with IMOJEV® Japanese Encephalitis Vaccine in the region. The partnership addresses significant unmet medical needs for pediatric enterovirus vaccines in ASEAN markets with Vietnam's 1.36 million annual births.
• WHO COVID-19 Technology Access Pool (C-TAP)coreStrategic or Co-development Partner · 29 August 2023First private manufacturer to out-license COVID-19 vaccine technology through WHO C-TAP initiative and Medicines Patent Pool (MPP). MVC provides technology transfer of IP, proprietary know-how, and staff training to enable manufacturers in low and middle-income countries to produce the vaccine. The partnership demonstrates MVC's commitment to global health equity and sets precedent for future technology sharing.
• CEPI (Coalition for Epidemic Preparedness Innovations)minorStrategic or Co-development Partner · 2 December 2021Co-funding partnership with CEPI for mix-and-match booster trial of COVID-19 vaccines, supporting global pandemic preparedness research.
• Australia Therapeutic Goods Administration (TGA)minorStrategic or Co-development Partner · 22 November 2021MVC's COVID-19 vaccine received provisional determination from Australia's TGA, enabling pathway for regulatory approval and potential supply to Australian markets.
• WHO COVID-19 Solidarity Trial VaccinescoreStrategic or Co-development Partner · 27 October 2021MVC-COV1901 selected for inclusion in WHO's global COVID-19 Solidarity Trial Vaccines, a landmark international clinical trial evaluating multiple COVID-19 vaccines. This validates the vaccine's scientific merit and potential for global impact.
• Vietnam National Institute of Hygiene and Epidemiology (NIHE)coreStrategic or Co-development Partner · 3 November 2020Partnership to develop COVID-19 vaccine in Vietnam, including Phase III clinical trial collaboration for EV71 vaccine conducted in both Taiwan and Vietnam.
• Dynavax TechnologiescoreTechnology or Integration · 24 July 2020Collaboration for COVID-19 vaccine MVC-COV1901 using Dynavax's CpG 1018 adjuvant. The CpG adjuvant enhances immune response to the recombinant spike protein vaccine antigen. Dynavax's CpG 1018 is a TLR9 agonist that improves vaccine efficacy.
• Serum Institute of India (SII)minorStrategic or Co-development Partner · 3 May 2018Signed MoU with SII to address local measles outbreak, demonstrating collaboration during public health emergencies.
• GC Pharma (GCC)minorStrategic or Co-development Partner · 23 April 2018Collaboration with GC Pharma to commercialize quadrivalent influenza vaccine in Taiwan, leveraging GC Pharma's manufacturing and regulatory expertise.
• Taiwan CDCminorStrategic or Co-development Partner · 27 April 2017Technology transfer of BCG and Snake Anti-venom production from Taiwan CDC, expanding MVC's product portfolio beyond vaccines.
• US NIH (National Institutes of Health)coreTechnology or Integration · 17 November 2016License from US NIH to develop dengue vaccine in 17 countries initially, later expanded to 26 countries. Also collaborated on COVID-19 vaccine development with NIH technology.
• National Health Research Institutes (NHRI) TaiwancoreStrategic or Co-development Partner · 6 August 2015Technology transfer from NHRI for EV-A71 vaccine development. MVC pursued Phase II clinical validation of safety, dose exploration, and cross-protection with subtypes following the technology transfer. NHRI originally developed the EV71 vaccine technology that MVC commercialized.

Scale indicators8 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Adimmune Corporation: Adimmune is a Taiwan-listed vaccine manufacturer producing influenza and pandemic vaccines. Direct competitor sharing the same domestic Taiwan vaccine market, including supply into national immunization programs with cell-based production capabilities.
• GC Pharma (Green Cross): GC Pharma is a Korean biological products company developing and manufacturing vaccines, plasma products, and biologics. MVC already has a commercial collaboration with GC Pharma on QIV in Taiwan, indicating closely overlapping platforms and target markets in Asia-Pacific vaccines.

Others

• Dynavax Technologies: Dynavax Technologies is a US biopharmaceutical company whose CpG 1018 adjuvant is used in MVC-COV1901 and in HEPLISAV-B. Listed because of an active technology collaboration with MVC rather than direct competition; relevant as a partner/adjacent enablement company in the vaccine industry.

Emerging players

• Sinovac Biotech: Sinovac is a Chinese vaccine manufacturer with commercial inactivated viral vaccines including COVID-19 and enterovirus-related products, supplying Asian and emerging-market national programs. Comparable as an Asia-headquartered vaccine specialist with similar government-procurement business model.
• Bharat Biotech: Bharat Biotech is an Indian vaccine manufacturer with WHO-prequalified products across pediatric and emerging infectious disease vaccines, including inactivated whole-virus platforms. Comparable on biological manufacturing expertise, emerging-market regulatory positioning, and pediatric vaccine focus.
• Novavax: Novavax developed a recombinant SARS-CoV-2 spike protein vaccine (Nuvaxovid) using adjuvant technology, paralleling MVC-COV1901's recombinant spike + CpG adjuvant architecture. Comparable on recombinant protein subunit vaccine platform and adjuvant partnerships.

Broad incumbents

• Serum Institute of India: Serum Institute of India is the world's largest vaccine manufacturer by doses, supplying pediatric and emerging-market immunization programs globally. Comparable on the model of cost-efficient, large-scale vaccine supply into emerging-market public health channels.
• Sanofi Pasteur: Sanofi Pasteur is the vaccine division of Sanofi and one of the largest global vaccine manufacturers with broad pediatric, influenza, and travel vaccine portfolios. Comparable as a broad incumbent operating in the same vaccine categories (EV71-adjacent, influenza) across global markets.
• CSL Limited (Seqirus): CSL Limited is an Australian-headquartered global biotherapeutics company with a large vaccines franchise (Seqirus) producing cell-based and adjuvanted influenza vaccines. Comparable on cell-based vaccine manufacturing, PIC/S-grade facilities, and Asia-Pacific vaccine market presence.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medigen-vaccine-biologics-corporation

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medigen Vaccine Biologics